Blog

Croissy-Beaubourg and Montpellier, July 11, 2016 – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, PEA-PME eligible), a company specializing in in vitro diagnostics and theranostics, is today announcing Vincent Fert’s appointment to the Company’s Board of Directors.

Vincent Fert is joining Theradiag’s Board of Directors, taking over the duties of Jean‑Paul Prieels. Vincent was the Co-Founder and Chief Executive Officer of Ipsogen. He subsequently became Vice President, Program Lead Personalized Healthcare at Qiagen, and is currently Chairman and Chief Executive Officer of HalioDX, a company he co-founded that develops diagnostic tests measuring the immune response in oncology.

Prof. Gérard Tobelem, Theradiag’s Chairman, commented: “We are delighted that Vincent Fert has joined our Board of Directors. Vincent has over 30 years’ experience in in vitro diagnostics and has held various positions with listed companies. He brings his vast international experience of the diagnostics industry and his know-how in the development of innovative diagnostic solutions. He will have a crucial impact on Theradiag’s development.”

Vincent Fert, a member of the Board of Directors, added: “I am thrilled to be joining Theradiag’s Board of Directors today. Biotherapy monitoring has provided a major leap forward for patients and the doctors treating them. I am extremely pleased to be supporting Theradiag’s development in personalized medicine.”

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer, auto-immune and inflammatory diseases and HIV/AIDS. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 75 employees.

For more information about Theradiag, please visit our website: www.theradiag.com